- Chevron Corp (CVX) Reports Profit of $201 million in third quarter 2020
- Overstock.com, Inc. (OSTK) Stumbles After Reported Q3 2020 Financial Results
- What's the Analyst Recommendation for Rekor Systems Inc. (REKR)?
- Let’s Take a Look at Bunge Limited (BG) Stock
- Is it Time to Sell/Buy Callaway Golf Company (ELY) Stock After Recent Trade?
GenMark Diagnostics Inc. (GNMK) share price plummeted -1.33% with the closing price of $14.11 on Friday. GenMark Diagnostics Inc. stock has an exchanging volume of 4.34 million shares, which is high, contrasted with its 3-months average volume of 1.15M shares. Its market capitalization has now reached to $1.02B and analysts have a consensus target price of $20.60 in the 12-month period.
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA on October 8, 2020 news published at Yahoo.
Needham announced it was Reiterated coverage of GenMark Diagnostics Inc. in a research note on August 05, 2020. The analysts assigned a Buy rating to the stock with a price target of $22. Needham rated the stock as a Buy in a research noted published on July 08, 2020. Needham rated the stock as a Buy in a research note published on May 05, 2020.
GNMK Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, GNMK price has rose by 0.79%. In the course of past three months sees the stock go down around -16.71%, while it has gain 127.58% over the past six months and 193.35% since the start of the year.
GNMK Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 40.09 billion, which was higher than the gauge of 39.26M made by certain experts. For that equivalent quarter, GenMark Diagnostics Inc. posted -$0.07 earnings per share (EPS) which was above the consensus estimate of -$0.09 by $0.02, which represents to an expansion by 22.20%.
GNMK Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on GenMark Diagnostics Inc. has seen its stock exchanging -32.42% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +33.11% above its three-month low. A more extensive look sees GNMK exchanging -32.42% beneath its 52-week high and 319.94% above from its 52-week low price.
GNMK Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 8.91%, while it has a month to month instability of 6.99%. The company has an ATR (Average True Range) of 0.97 and a beta factor of 3.21.